FDA approves vaccine Menhibrix (GSK)for bacterial diseases

The FDA on 14 June 2012 approved Menhibrix, from Glaxo Smith Kline, a combined meningococcal disease (serogroups C and Y) and Haemophilus influenzae type b (Hib) conjugated vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b. Diseases caused by the bacteria Neisseria meningitidis (meningococcal disease) and Haemophilus influenzae type b (Hib disease) can be life-threatening. These bacteria can infect the bloodstream causing sepsis, and the lining that surrounds the brain and spinal cord causing meningitis. In young children, Neisseria meningitidis and Haemophilus influenzae type b are important causes of bacterial meningitis. Without vaccination, children younger than two years are susceptible to these serious illnesses.